To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Epidarex sells Enterprise Therapeutics’ lead program
Roche is acquiring Enterprise Therapeutics' lead program from Epidarex Capital.
